Back to Foresite Capital Management VI LLC
Foresite Capital Management VI LLC
Q3 2026 13F filing
Updated 6 days ago22 disclosed positions worth $566.4M
Portfolio value
$566.4M
Total holdings
22
New positions
0
Closed positions
0
Increased
0
Decreased
0
Turnover
—
Filed
2026-11-16
Full holdings
Every line item disclosed in Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | C CG Oncology, Inc. | $149.5M | 2.11M | 26.41% | — |
| 2 | K Korsana Biosciences, Inc. | $45.8M | 1.43M | 8.09% | — |
| 3 | L Latigo Biotherapeutics, Inc. | $36.8M | 2.20M | 6.50% | — |
| 4 | S Seaport Therapeutics, Inc. | $35.9M | 1.78M | 6.34% | — |
| 5 | D Denali Therapeutics Inc. | $33.4M | 1.62M | 5.90% | — |
| 6 | P Parabilis Medicines, Inc. | $32.3M | 999.0K | 5.70% | — |
| 7 | A ALUMIS INC. | $31.4M | 4.25M | 5.54% | — |
| 8 | M AGIOS PHARMACEUTICALS, INC. | $27.5M | 827.1K | 4.86% | — |
| 9 | V Verastem, Inc. | $25.3M | 3.15M | 4.47% | — |
| 10 | G GH Research PLC | $22.1M | 940.5K | 3.90% | — |
| 11 | C Corvus Pharmaceuticals, Inc. | $21.1M | 1.83M | 3.72% | — |
| 12 | K Kymera Therapeutics, Inc. | $16.4M | 146.3K | 2.89% | — |
| 13 | A ArriVent BioPharma, Inc. | $14.8M | 490.3K | 2.62% | — |
| 14 | O Obsidian Therapeutics, Inc. | $12.6M | 916.1K | 2.22% | — |
| 15 | J Jade Biosciences, Inc. | $12.5M | 886.7K | 2.20% | — |
| 16 | H Hinge Health, Inc. | $10.5M | 108.1K | 1.86% | — |
| 17 | A Aura Biosciences, Inc. | $8.4M | 1.33M | 1.48% | — |
| 18 | B Beam Therapeutics Inc. | $8.1M | 330.0K | 1.42% | — |
| 19 | Z Zura Bio Ltd | $7.3M | 1.76M | 1.29% | — |
| 20 | N Minerva Neurosciences, Inc. | $6.7M | 1.99M | 1.17% | — |
| 21 | I Disc Medicine, Inc. | $4.5M | 68.5K | 0.79% | — |
| 22 | E Entera Bio Ltd. | $3.6M | 1.23M | 0.63% | — |